top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (225 pages)
Disciplina 362.1962414
Altri autori (Persone) BhadadaSanjay Kumar
KatareO. P
Soggetto topico Covid-19 vaccines
Public policy
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-805-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19.
Hydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19.
PARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT.
BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover.
Record Nr. UNINA-9910794531603321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (223 pages)
Disciplina 616.2414
Altri autori (Persone) BhadadaSanjay K
KatareO. P
Soggetto topico COVID-19 (Disease) - Prevention
COVID-19 (Disease) - Economic aspects
COVID-19 (Disease) - Social aspects
COVID-19 Pandemic, 2020-
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-808-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Chapter 1 -- Sunishtha1, Govind Singh1 and Sanju Nanda1,* -- INTRODUCTION -- THE ATHENIAN PLAGUE -- PLAGUE OF JUSTINIAN -- THE BLACK DEATH -- SPANISH FLU -- AIDS -- SMALLPOX -- SARS -- SWINE FLU OR H1N1 PANDEMIC -- EBOLA -- COVID-19 -- ORIGIN OF CORONAVIRUS -- TYPES OF CORONAVIRUSES -- DISEASE ASSOCIATED WITH CORONAVIRUSES -- MURINE HEPATITIS VIRUS (MHV) -- Central Nervous System -- Hepatitis -- Pneumonitis -- BOVINE CORONAVIRUS -- HUMAN CORONAVIRUS -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 2 -- Hitesh Malhotra1,*, Anjoo Kamboj1 and Peeyush Kaushik1 -- INTRODUCTION -- GENOMIC STRUCTURE OF CORONAVIRUS -- STRUCTURAL PROTEINS -- Spike Protein -- Small Membrane Protein -- Membrane Protein -- Hemagglutinin-Esterase -- Nucleocapsid and Internal Proteins -- Replicase Protein -- VIRAL CYCLE -- OUTBREAKS OF CORONAVIRUS -- Porcine Coronavirus -- Avian Coronavirus -- Feline Coronavirus -- Bovine Coronavirus -- Murine Coronavirus -- Human Coronavirus -- SARS-CoV -- MERS-CoV -- COVID-19 -- Introduction -- Chronology of COVID-19 -- Symptoms -- Transmission -- Treatment -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 3 -- Kamya Goyal1,2,#, Shammy Jindal1,#, Tarun Kumar3, Jugnu Goyal4, Reena Sharma5, Ravinder Singh6 and Samir Mehndiratta7,8,* -- INTRODUCTION -- GEOGRAPHICAL DISTRIBUTION -- GLOBAL EPIDEMIOLOGY OF COVID-19 -- Effect of Age, Sex and other Factors on Covid-19-Related Deaths -- COVID-19 CASE COMPARISONS IN DIFFERENT REGION OF WORLD (WORLD HEALTH ORGANIZATION, 2020) -- COVID-19 IN INDIA -- REPORT BY ICMR ON COVID-19 ABOUT CONTAINMENT ZONE IN INDIA -- NATIONAL RESPONSES ON COVID-19 WORLDWIDE.
Asia -- China -- South Korea -- Middle Eastern -- Iran -- Europe -- Spain -- France -- North America -- United States -- South America -- Africa -- Oceania -- EFFECT OF LOCKDOWN ON COVID-19 CASES IN TOP TEN MOST AFFECTED COUNTRIES OF WORLD -- THE ROLE OF WHO AND INGOS FOR PROVIDING DATA IN COVID-19 -- OUTCOMES FROM SOME PUBLISHED REPORTS ON COVID-19 EPIDEMIOLOGY -- Herd Immunity-COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 4 -- Anirban Ghosh1 and Shamsher Singh1,* -- INTRODUCTION -- TRANSMISSION OF COV -- Virus Life Cycle -- Role of Structural Proteins in The Pathogenesis -- A. Spike Protein -- B. Hemagglutinin-Esterase (HE) Protein -- C. Membrane (M) Protein -- D. Small Envelop (E) Protein -- E. Nucleocapsid (N) Protein and Internal (I) Protein -- F. Replicase Proteins -- G. CoV Associated Protein -- Pathophysiology from a Cell Biology Perspective -- Phase I. Asymptomatic Stage (First 1-2 Days of Infection) -- Phase II. Upper Airway and Conducting Airway Response (Next Few Days) -- Phase III. Hypoxia, Ground-glass Infiltrates, Progression to ARDs -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 5 -- Jasleen Kaur1, Baljinder Singh2, Bikash Medhi3 and Gurpreet Kaur1,* -- INTRODUCTION -- CLINICAL PRESENTATIONS OF COVID-19 INFECTION -- INTER-INDIVIDUAL VARIATIONS IN CLINICAL PRESENTATIONS DUE TO DIFFERENTIAL SUSCEPTIBILITY TOWARDS COVID-19 -- Neonates or Newborns (Upto 1 Month) -- Infants (1 Month-2 Years), Children (2-10 Years) -- Adolescent (11-19 Years), Young (20-35 Years) and Middle Aged (36-59 Years) Patients -- Elderly (> -- 60 Years) and Older (> -- 80 Years) Patients -- ACE2 -- Gender -- Blood Group -- Previous Immunization -- COMORBIDITY -- CONCLUSION.
LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 6 -- Richa Deshpande1,#, Aishwarya Joshi1,#, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: A PANDEMIC DISEASE -- COVID-19: EARLY DETECTION BASED ON SYMPTOMS -- Clinical Analysis -- Hematological Analysis -- Chest CT -- COVID-19: MOLECULAR DETECTION OF VIRUS -- RT-PCR Based Assays -- Loop Mediated Isothermal Amplification (LAMP) -- CRISPR-Isothermal Amplification Based Assays -- Microarrays -- Metagenomic Sequencing Based Methods -- Gold Nanoparticles-Based Colorimetric Assay -- COVID-19: SERIOLOGICAL AND IMMUNOLOGICAL BASED DETECTION -- BIOMARKER IDENTIFICATION: APPROACH OF SEROLOGICAL PLATFORM -- Antibody Biomarkers -- Antigen Biomarkers -- Procalcitonin and Interleukin-6 as Prognostic COVID-19 Biomarkers -- SEROLOGICAL AND IMMUNOLOGICAL ASSAYS -- Enzyme-linked Immunosorbent Assay (ELISA) -- Lateral Flow Immunoassay -- Neutralization Assays -- Luminescence-based Immunoassays -- Biosensor Tests -- Rapid Antigen Tests -- CONCLUDING REMARKS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index.
Altri titoli varianti COVID-19
Record Nr. UNINA-9910794540303321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (223 pages)
Disciplina 616.2414
Altri autori (Persone) BhadadaSanjay K
KatareO. P
Soggetto topico COVID-19 (Disease) - Prevention
COVID-19 (Disease) - Economic aspects
COVID-19 (Disease) - Social aspects
COVID-19 Pandemic, 2020-
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-808-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Chapter 1 -- Sunishtha1, Govind Singh1 and Sanju Nanda1,* -- INTRODUCTION -- THE ATHENIAN PLAGUE -- PLAGUE OF JUSTINIAN -- THE BLACK DEATH -- SPANISH FLU -- AIDS -- SMALLPOX -- SARS -- SWINE FLU OR H1N1 PANDEMIC -- EBOLA -- COVID-19 -- ORIGIN OF CORONAVIRUS -- TYPES OF CORONAVIRUSES -- DISEASE ASSOCIATED WITH CORONAVIRUSES -- MURINE HEPATITIS VIRUS (MHV) -- Central Nervous System -- Hepatitis -- Pneumonitis -- BOVINE CORONAVIRUS -- HUMAN CORONAVIRUS -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 2 -- Hitesh Malhotra1,*, Anjoo Kamboj1 and Peeyush Kaushik1 -- INTRODUCTION -- GENOMIC STRUCTURE OF CORONAVIRUS -- STRUCTURAL PROTEINS -- Spike Protein -- Small Membrane Protein -- Membrane Protein -- Hemagglutinin-Esterase -- Nucleocapsid and Internal Proteins -- Replicase Protein -- VIRAL CYCLE -- OUTBREAKS OF CORONAVIRUS -- Porcine Coronavirus -- Avian Coronavirus -- Feline Coronavirus -- Bovine Coronavirus -- Murine Coronavirus -- Human Coronavirus -- SARS-CoV -- MERS-CoV -- COVID-19 -- Introduction -- Chronology of COVID-19 -- Symptoms -- Transmission -- Treatment -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 3 -- Kamya Goyal1,2,#, Shammy Jindal1,#, Tarun Kumar3, Jugnu Goyal4, Reena Sharma5, Ravinder Singh6 and Samir Mehndiratta7,8,* -- INTRODUCTION -- GEOGRAPHICAL DISTRIBUTION -- GLOBAL EPIDEMIOLOGY OF COVID-19 -- Effect of Age, Sex and other Factors on Covid-19-Related Deaths -- COVID-19 CASE COMPARISONS IN DIFFERENT REGION OF WORLD (WORLD HEALTH ORGANIZATION, 2020) -- COVID-19 IN INDIA -- REPORT BY ICMR ON COVID-19 ABOUT CONTAINMENT ZONE IN INDIA -- NATIONAL RESPONSES ON COVID-19 WORLDWIDE.
Asia -- China -- South Korea -- Middle Eastern -- Iran -- Europe -- Spain -- France -- North America -- United States -- South America -- Africa -- Oceania -- EFFECT OF LOCKDOWN ON COVID-19 CASES IN TOP TEN MOST AFFECTED COUNTRIES OF WORLD -- THE ROLE OF WHO AND INGOS FOR PROVIDING DATA IN COVID-19 -- OUTCOMES FROM SOME PUBLISHED REPORTS ON COVID-19 EPIDEMIOLOGY -- Herd Immunity-COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 4 -- Anirban Ghosh1 and Shamsher Singh1,* -- INTRODUCTION -- TRANSMISSION OF COV -- Virus Life Cycle -- Role of Structural Proteins in The Pathogenesis -- A. Spike Protein -- B. Hemagglutinin-Esterase (HE) Protein -- C. Membrane (M) Protein -- D. Small Envelop (E) Protein -- E. Nucleocapsid (N) Protein and Internal (I) Protein -- F. Replicase Proteins -- G. CoV Associated Protein -- Pathophysiology from a Cell Biology Perspective -- Phase I. Asymptomatic Stage (First 1-2 Days of Infection) -- Phase II. Upper Airway and Conducting Airway Response (Next Few Days) -- Phase III. Hypoxia, Ground-glass Infiltrates, Progression to ARDs -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 5 -- Jasleen Kaur1, Baljinder Singh2, Bikash Medhi3 and Gurpreet Kaur1,* -- INTRODUCTION -- CLINICAL PRESENTATIONS OF COVID-19 INFECTION -- INTER-INDIVIDUAL VARIATIONS IN CLINICAL PRESENTATIONS DUE TO DIFFERENTIAL SUSCEPTIBILITY TOWARDS COVID-19 -- Neonates or Newborns (Upto 1 Month) -- Infants (1 Month-2 Years), Children (2-10 Years) -- Adolescent (11-19 Years), Young (20-35 Years) and Middle Aged (36-59 Years) Patients -- Elderly (> -- 60 Years) and Older (> -- 80 Years) Patients -- ACE2 -- Gender -- Blood Group -- Previous Immunization -- COMORBIDITY -- CONCLUSION.
LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 6 -- Richa Deshpande1,#, Aishwarya Joshi1,#, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: A PANDEMIC DISEASE -- COVID-19: EARLY DETECTION BASED ON SYMPTOMS -- Clinical Analysis -- Hematological Analysis -- Chest CT -- COVID-19: MOLECULAR DETECTION OF VIRUS -- RT-PCR Based Assays -- Loop Mediated Isothermal Amplification (LAMP) -- CRISPR-Isothermal Amplification Based Assays -- Microarrays -- Metagenomic Sequencing Based Methods -- Gold Nanoparticles-Based Colorimetric Assay -- COVID-19: SERIOLOGICAL AND IMMUNOLOGICAL BASED DETECTION -- BIOMARKER IDENTIFICATION: APPROACH OF SEROLOGICAL PLATFORM -- Antibody Biomarkers -- Antigen Biomarkers -- Procalcitonin and Interleukin-6 as Prognostic COVID-19 Biomarkers -- SEROLOGICAL AND IMMUNOLOGICAL ASSAYS -- Enzyme-linked Immunosorbent Assay (ELISA) -- Lateral Flow Immunoassay -- Neutralization Assays -- Luminescence-based Immunoassays -- Biosensor Tests -- Rapid Antigen Tests -- CONCLUDING REMARKS -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index.
Altri titoli varianti COVID-19
Record Nr. UNINA-9910817553703321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
COVID-19
COVID-19
Autore Mittal Neeraj
Edizione [1st ed.]
Pubbl/distr/stampa Sharjah : , : Bentham Science Publishers, , 2021
Descrizione fisica 1 online resource (225 pages)
Disciplina 362.1962414
Altri autori (Persone) BhadadaSanjay Kumar
KatareO. P
Soggetto topico Covid-19 vaccines
Public policy
Soggetto non controllato Communicable Diseases
Medical
ISBN 1-68108-805-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Prevention of COVID-19: Facts to Overcome the Myths -- Rajesh Kumar1, Mangesh Pradeep Kulkarni1, Sheetu Wadhwa1 and Soundappan Kathirvel2,* -- INTRODUCTION -- MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS -- Personal Protective Equipment (PPE) -- Head Covers -- Face Shield -- Mask -- Goggles -- Gloves -- Shoe Covers -- Gowns or Coveralls -- SANITIZATION AND DISINFECTION -- Hand Hygiene -- For Public -- Prevention of COVID-19 Among Frontline Healthcare Workers -- Cleaning of Vegetables-Fruits -- Safe Handling of Currency and Paper Documents -- Cough or Respiratory Etiquettes -- Precautions to be Taken While Coughing/Sneezing or Any Physical Contact -- Spitting or Littering in Public -- Disinfection of Public Places -- Disposal and Disinfection of PPEs -- WATER TREATMENT AND WASTE MANAGEMENT -- Management of Water and Faecal Waste -- Safety of Water Supplies -- SOCIAL MEASURES -- Physical Distancing -- Quarantine and Isolation -- Home Quarantine -- Institutional Quarantine -- Staff Guidelines -- Utility Guidelines -- Lockdown and Travel Restrictions -- Zonal Classification of the Geography -- PROPHYLAXIS FOR COVID-19 -- Dietary Recommendations for the Prevention of COVID-19 -- General Measures -- Medicinal Plant Measures/Procedures -- Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient -- REGULAR SCREENING -- PRECAUTIONS FOR TRAVEL -- CONCLUSION -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Treatment Methods for Coronavirus Disease-19 -- Kuldeep Kumar1, Sonal1, Pankaj Bhatia1, Dhandeep Singh1, Amteshwar S. Jaggi1 and Nirmal Singh1,* -- INTRODUCTION -- OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19.
Hydroxychloroquine -- HCQ in Treatment of COVID-19 -- Remdesivir -- Remdesivir in Treatment of COVID-19 -- Lopinavir/Ritonavir -- Lopinavir/Ritonavir in Treatment of COVID-19 -- Favipiravir -- Favipiravir in Treatment of COVID-19 -- Azithromycin (AZ) -- AZ in COVID-19 Treatment -- Arbidol -- Arbidol in Treatment of COVID-19 -- Ribavirin -- Ribavirin in COVID-19 Treatment -- Teicoplanin -- Teicoplanin in COVID-19 Treatment -- Ivermectin -- Ivermectin in Treatment of COVID-19 -- Nitazoxanide -- Nitazoxanide in COVID-19 Treatment -- Corticosteroids -- Corticosteroids in the Treatment of COVID-19 -- Immuno Modulating Agents-Interferons (IFN's) -- IFN's in Treatment of COVID-19 -- Monoclonal Antibody Therapy -- 80R Immunoglobulin G1 (IgGI) -- CR3014 -- Monoclonal Antibody Therapy in COVID-19 Treatment -- Tocilizumab -- Sarilumab -- Limitations and Suggestions Regarding mAb's -- Triple Therapy -- Miscellaneous Drugs -- Herbal Drugs for COVID-19 -- Glycyrrhizin -- Glycyrrhizin in COVID-19 -- Hesperetin -- Baicalin -- Scutellarin -- Plasma Therapy -- Plasma Therapy in the Treatment of COVID-19 -- Potential of Stem Cell Therapy in COVID-19 -- BCG Vaccine -- VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19 -- CONCLUSION -- LIST OF ABBREVIATIONS -- AUTHORS CONTRIBUTION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 and Mortality -- Rimesh Pal1 and Sanjay Kumar Bhadada1,* -- INTRODUCTION -- REPRESENTING MORTALITY - MORTALITY RATE VS. CASE-FATALITY RATE -- FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE -- REPORTING COVID-19-RELATED DEATHS -- COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES -- COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS -- CAUSES OF DEATH IN COVID-19.
PARAMETERS PREDICTING MORTALITY IN COVID-19 -- Clinical Parameters -- Age -- Gender -- Symptoms -- Complications -- Comorbid Illness -- Smoking -- Secondary Infections -- Laboratory Parameters -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Long Term Complications of COVID-19 -- Ankita Sood1, Bimlesh Kumar1,*, Indu Melkani1, Archit Sood2, Pankaj Prashar1, Anamika Gautam1, Kardam Joshi3 and Dhara Patel3 -- INTRODUCTION -- LONG TERM COMPLICATIONS OF COVID-19 -- COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES -- Diabetes Mellitus (DM) -- Hematological Complications -- Cardiovascular Diseases -- Central Nervous System Complications -- Viral Encephalitis -- Infectious Toxic Encephalopathy and Cerebrovascular Disease -- Chronic Kidney Disease (CKD) -- Asthma and Respiratory Disorders -- Rheumatoid Arthritis (RA) -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Vaccine Development -- Priya Sharma1,#, Shivani Joshi1,#, Aishwarya Joshi1, Nikunj Tandel1 and Rajeev K. Tyagi2,* -- COVID-19: VACCINE DEVELOPMENT -- COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM -- TYPES OF VACCINES AND THEIR CHARACTERISTICS -- Live-attenuated Virus and Inactivated Whole Virus Vaccines -- Subunit Vaccines -- Vaccines Based on Virus-like Particles (VLPs) -- Viral Vector-based Vaccines -- DNA Vaccines -- NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS -- Serum Albumin Strategy -- Natural Product (Plant) Based Technology -- Nanotechnology and Material Science -- mRNA Based Approaches -- ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS -- Animal Models Currently in Practice -- Humanized Mice Models -- Novel Approach of Using Zebrafish (Their Advantages) -- CURRENT STATUS OF VACCINE DEVELOPMENT.
BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES -- Lessons from Previous Vaccine Development -- LIST OF ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Future of COVID-19 Treatment -- Sahil Arora1,#, Manvendra Kumar1,#, Gaurav Joshi1,* and Raj Kumar1,* -- INTRODUCTION -- DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE -- DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE -- ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE -- DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19 -- MISCELLANEOUS -- DISCUSSION AND CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover.
Record Nr. UNINA-9910825895903321
Mittal Neeraj  
Sharjah : , : Bentham Science Publishers, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
Pubbl/distr/stampa Singapore : , : Bentham Science Publishers, , [2021]
Descrizione fisica 1 online resource (276 pages)
Disciplina 614.592414
Soggetto topico Coronavirus infections
Soggetto non controllato Communicable Diseases
Medical
ISBN 981-14-8187-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910794438803321
Singapore : , : Bentham Science Publishers, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
The COVID-19 pandemic : epidemiology, molecular biology and therapy / / edited by Shama Parveen
Pubbl/distr/stampa Singapore : , : Bentham Science Publishers, , [2021]
Descrizione fisica 1 online resource (276 pages)
Disciplina 614.592414
Soggetto topico Coronavirus infections
Soggetto non controllato Communicable Diseases
Medical
ISBN 981-14-8187-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910828840903321
Singapore : , : Bentham Science Publishers, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Current HIV/AIDS reports
Current HIV/AIDS reports
Pubbl/distr/stampa [Philadelphia, Pa.] : , : Current Science, , 2004-
Disciplina 614.5
Soggetto topico AIDS (Disease)
HIV infections
Soggetto genere / forma Periodicals.
Soggetto non controllato Communicable Diseases
ISSN 1548-3576
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNISA-996198110103316
[Philadelphia, Pa.] : , : Current Science, , 2004-
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Emerging microbes & infections
Emerging microbes & infections
Pubbl/distr/stampa New York, : NPG, 2012-2018
Descrizione fisica 1 online resource
Soggetto topico Emerging infectious diseases
Emerging infectious diseases - Pathogenesis
Emerging infectious diseases - Epidemiology
Communicable Diseases, Emerging
Soggetto genere / forma Fulltext
Internet Resources.
Periodicals.
Periodical
Soggetto non controllato Communicable Diseases
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti EMI
Emerging microbes and infections
Record Nr. UNISA-996321888703316
New York, : NPG, 2012-2018
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Evidence-based infectious diseases / / edited by Dominik Mertz, Fiona Smaill, Nick Daneman
Evidence-based infectious diseases / / edited by Dominik Mertz, Fiona Smaill, Nick Daneman
Edizione [Third edition.]
Pubbl/distr/stampa Hoboken, New Jersey : , : Wiley Blackwell, , 2018
Descrizione fisica 1 online resource (322 pages)
Disciplina 616.9
Collana Evidence-Based Medicine Ser
Soggetto topico Evidence-based medicine
Communicable diseases
Soggetto non controllato Communicable Diseases
Evidence-Based Medicine
Medical
ISBN 1-119-26035-3
1-119-26033-7
1-119-26036-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto List of Contributors vii Preface xi 1 Introduction to Evidence‐based Infectious Diseases 1Dominik Mertz, Nick Daneman, and Fiona Smaill Part 1 Specific Diseases 11 2 Skin and Soft‐tissue Infections 13Douglas Austgarden and Guilio DiDiodato 3 Bone and Joint Infections 23Nora Renz and Andrej Trampuz 4 Infective Endocarditis 37Bahareh Ghadaki and Deborah Yamamura 5 Meningitis and Encephalitis 53Christopher E. Kandel and Wayne L. Gold 6 Community‐acquired Pneumonia 73Mark Downing and Jennie Johnstone 7 Healthcare‐associated Pneumonia 81Jennie Johnstone and Mark Downing 8 Tuberculosis 87Peter Daley and Marek Smieja 9 Clostridium Difficile Infection in Adults 99Louis Valiquette 10 Urinary Tract Infections 107Thomas Fekete 11 Sexually Transmitted Infections 127Courtney A. Thompson, Darrell H. S. Tan, and Kaede Sullivan 12 Human Immunodeficiency Virus (HIV) 149Ali Amini, Monique Andersson, Ravindra Gupta, and Brian Angus 13 Hepatitis 181Lise Bondy and Michael S. Silverman 14 Influenza 193Ashley Roberts and Joanne M. Langley 15 Critical Care 201Bram Rochwerg and Jocelyn A. Srigley Part 2 Special Populations 215 16 Infection Prevention and Control 217Graham M. Snyder and Eli N. Perencevich 17 Antimicrobial Stewardship 235Alainna J. Jamal and Andrew M. Morris 18 Infections in Neutropenic Hosts 251Eric J. Bow 19 Infections in General Surgery 269Paul A. Moroz and Christine H. Lee 20 Infections in Healthcare Workers 279Gregory W. Rose Index.
Record Nr. UNINA-9910526641803321
Hoboken, New Jersey : , : Wiley Blackwell, , 2018
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Infectious disease reports
Infectious disease reports
Pubbl/distr/stampa Pavia, Italy, : PAGEPress
Descrizione fisica 1 online resource
Soggetto topico Communicable diseases
Communicable Diseases
Infections
Infection Control
Soggetto genere / forma Case Reports.
Periodical
Fulltext
Internet Resources.
Periodicals.
Case studies.
Soggetto non controllato Communicable Diseases
ISSN 2036-7449
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti IDR
Record Nr. UNISA-996321401703316
Pavia, Italy, : PAGEPress
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui